ANGPTL4 gene E40K variation protects against obesity‐associated dyslipidemia in participants with obesity
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Objective: ANGPTL4 inhibits lipoprotein lipase in adipose tissue, regulating plasma triglycerides levels. In persons with obesity plasma ANGPTL4 levels have been positively correlated with body fat mass, TG levels and low HDL. A loss‐of‐function E40K mutation in ANGPTL4 prevents LPL inhibition, resulting in lower TGs and higher HDLc in the general population. Since obesity determines metabolic alterations and consequently is a major risk factor for cardiovascular disease, the aim was to explore if obesity‐related metabolic abnormalities are modified by the ANGPTL4‐E40K mutation. Methods: ANGPTL4‐E40K was screened in 1206 Italian participants, of which 863 (71.5%) with obesity. All subjects without diabetes underwent OGTT with calculation of indices of insulin‐sensitivity. Results: Participants with obesity carrying the E40K variant had significantly lower TG (p = 0.001) and higher HDLc levels (p = 0.024). Also in the whole population low TGs and high HDLc were confirmed in E40K carriers. In the obese subpopulation it was observed that almost all E40K carriers were within the lowest quartile of TGs (p = 1.1 × 10−9). E40K had no substantial effect of on glucose metabolism. Finally, none of the obese E40K carriers had T2D, and together with the favourable lipid profile, they resemble a metabolically healthy obese (MHO) phenotype, compared to 38% of E40E wild‐type obese that had diabetes and/or dyslipidaemia (p = 0.0106). Conclusions: In participants with obesity the ANGPTL4‐E40K variant protects against dyslipidemia. The phenotype of obese E40K carriers is that of a patient with obesity without metabolic alterations, similar to the phenotype described as metabolic healthy obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Skol, A. D., Scott, L. J., Abecasis, G. R., & Boehnke, M. (2006) · Nature Genetics · doi:10.1038/ng1706 · Cited by 1,286 · cited 1×
“Power analysis was performed by the Genetic Association Study (GAS) Power Calculator (Johnson JL, University of Michigan 2017) (20) commonly used to compute statistical power for one-stage genetic association studies.”
MethodRomeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511 · cited 3×
“This findings confirm and expand previous observations in the general population (1,3,9,15,16), demonstrating that also in participants with obesity, by definition at more risk for metabolic alterations, ANGPTL4 E40K variant is capable to ameliorate lipid levels.”
BackgroundResultSelf-citationEckel, N., Li, Y., Kuxhaus, O., Stefan, N., Hu, F. B., & Schulze, M. B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30137-2 · Cited by 457 · cited 1×
“Recently, in a large follow-up study of 30 years of women stratified as metabolically healthy by the absence of hypertension, diabetes and hypercholesterolemia, the authors observed that women with obesity who maintained a metabolically healthy phenotype during the follow-up still had an increased risk of CVD compared…”
BackgroundTriglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237 · cited 8×
“Because it is an inhibiting protein, loss-offunction (LoF) variants in ANGPTL4 such as E40K, act by enhancing adipose-specific LPL activity, resulting in lowering circulating TGs, a condition per se protective against cardiovascular disease (CVD) (11).”
BackgroundInfluentialJanssen, A. W. F., Katiraei, S., Bartosinska, B., Eberhard, D., Willems van Dijk, K., & Kersten, S. (2018) · Diabetologia · doi:10.1007/s00125-018-4583-5 · Cited by 96
Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?
Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30 · cited 2×
“This findings confirm and expand previous observations in the general population (1,3,9,15,16), demonstrating that also in participants with obesity, by definition at more risk for metabolic alterations, ANGPTL4 E40K variant is capable to ameliorate lipid levels.”
BackgroundResult
Cited by
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Chen, Y. Q., Pottanat, T. G., Siegel, R. W., Ehsani, M., Qian, Y.-W., Zhen, E. Y., Regmi, A., Roell, W. C., Guo, H., Luo, M. J., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000781 · Cited by 147
Singh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115
Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice
Spitler, K. M., Shetty, S. K., Cushing, E. M., Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87020-5 · Cited by 42
Metadata
- Authors
- Bailetti, D., Bertoccini, L., Mancina, R. M., Barchetta, I., Capoccia, D., Cossu, E., Pujia, A., Lenzi, A., Leonetti, F., Cavallo, M. G., Romeo, S., & Baroni, M. G.
- Venue
- Obesity Science & Practice
- Publisher
- Wiley
- Published
- 2018-12-26
- Volume
- 5
- Issue
- 1
- Pages
- 83-90
- ISSN
- 2055-2238 (ISSN-L)
- OpenAlex
- W2901460678
- Cited by
- 19
- References
- 8
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.